Security Reports > CRISPR Therapeutics

CRISPR Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://crisprtx.com  ᛫ 
Last updated May 26, 2020

CRISPR Therapeutics Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely CRISPR Therapeutics is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About CRISPR Therapeutics

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. The company has partnerships with Novartis and Regeneron.


Data Breaches and Security News


Security Report for CRISPR Therapeutics

Want a security rating for your organization?

This report shows a preliminary security rating for CRISPR Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare CRISPR Therapeutics's security performance with other companies